Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 145

1.

Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer.

Cillo AR, Kürten CHL, Tabib T, Qi Z, Onkar S, Wang T, Liu A, Duvvuri U, Kim S, Soose RJ, Oesterreich S, Chen W, Lafyatis R, Bruno TC, Ferris RL, Vignali DAA.

Immunity. 2020 Jan 14;52(1):183-199.e9. doi: 10.1016/j.immuni.2019.11.014. Epub 2020 Jan 7.

PMID:
31924475
2.

Copper-dependent ATP7B up-regulation drives the resistance of TMEM16A-overexpressing head-and-neck cancer models to platinum toxicity.

Vyas A, Duvvuri U, Kiselyov K.

Biochem J. 2019 Dec 19;476(24):3705-3719. doi: 10.1042/BCJ20190591.

PMID:
31790150
3.

Innovations in risk-stratification and treatment of Veterans with oropharynx cancer; roadmap of the 2019 Field Based Meeting.

Sandulache VC, Lei YL, Heasley LE, Chang M, Amos CI, Sturgis EM, Graboyes E, Chiao EY, Rogus-Pulia N, Lewis J, Madabhushi A, Frederick MJ, Sabichi A, Ittmann M, Yarbrough WG, Chung CH, Ferrarotto R, Mai W, Skinner HD, Duvvuri U, Gerngross P, Sikora AG.

Oral Oncol. 2019 Oct 21:104440. doi: 10.1016/j.oraloncology.2019.104440. [Epub ahead of print] No abstract available.

PMID:
31648864
4.

Genomic Correlates of Exceptional Response to ErbB3 Inhibition in Head and Neck Squamous Cell Carcinoma.

Faden DL, Gomez-Casal R, Alvarado D, Duvvuri U.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00174. Epub 2019 Mar 25. No abstract available.

5.

Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma Patients.

Duvvuri U, George J, Kim S, Alvarado D, Neumeister VM, Chenna A, Gedrich R, Hawthorne T, LaVallee T, Grandis JR, Bauman JE.

Clin Cancer Res. 2019 Oct 1;25(19):5752-5758. doi: 10.1158/1078-0432.CCR-18-3453. Epub 2019 Jul 15.

6.

Profiling the Stromal and Vascular Heterogeneity in Patient-derived Xenograft Models of Head and Neck Cancer: Impact on Therapeutic Response.

Folaron M, Merzianu M, Duvvuri U, Ferris RL, Seshadri M.

Cancers (Basel). 2019 Jul 6;11(7). pii: E951. doi: 10.3390/cancers11070951.

7.

HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma.

Meister KS, Godse NR, Khan NI, Hedberg ML, Kemp C, Kulkarni S, Alvarado D, LaVallee T, Kim S, Grandis JR, Duvvuri U.

Sci Rep. 2019 Jun 24;9(1):9130. doi: 10.1038/s41598-019-45589-y.

8.

Reconstruction of TORS oropharyngectomy defects with the nasoseptal flap via transpalatal tunnel.

Turner MT, Geltzeiler M, Albergotti WG, Duvvuri U, Ferris RL, Kim S, Wang EW.

J Robot Surg. 2019 Jun 10. doi: 10.1007/s11701-019-00984-5. [Epub ahead of print]

PMID:
31183606
9.

Early squamous cell carcinoma of the oral tongue with histologically benign lymph nodes: A model predicting local control and vetting of the eighth edition of the American Joint Committee on Cancer pathologic T stage.

Sridharan S, Thompson LDR, Purgina B, Sturgis CD, Shah AA, Burkey B, Tuluc M, Cognetti D, Xu B, Higgins K, Hernandez-Prera JC, Guerrero D, Bundele MM, Kim S, Duvvuri U, Ferris RL, Gooding WE, Chiosea SI.

Cancer. 2019 Sep 15;125(18):3198-3207. doi: 10.1002/cncr.32199. Epub 2019 Jun 7.

PMID:
31174238
10.

VHA Practice Guideline Recommendations for Diffuse Gliomas.

Kulich S, Becker D, Dacic S, Duvvuri U, Ehsan A, Gutkin D, Hou P, Icardi M, Lyle P, Lynch J, Montgomery B, Passero V, Przygodzki R, Colman H.

Fed Pract. 2018 Aug;35(Suppl 5):S28-S35.

11.

Use of nonsteroidal anti-inflammatory drugs predicts improved patient survival for PIK3CA-altered head and neck cancer.

Hedberg ML, Peyser ND, Bauman JE, Gooding WE, Li H, Bhola NE, Zhu TR, Zeng Y, Brand TM, Kim MO, Jordan RCK, VandenBerg S, Olivas V, Bivona TG, Chiosea SI, Wang L, Mills GB, Johnson JT, Duvvuri U, Ferris RL, Ha P, Johnson DE, Grandis JR.

J Exp Med. 2019 Feb 4;216(2):419-427. doi: 10.1084/jem.20181936. Epub 2019 Jan 25.

12.

Novel minimally invasive transoral surgery bleeding model implemented in a nationwide otolaryngology emergencies bootcamp.

Sahovaler A, Eibling DE, Bruni I, Duvvuri U, MacNeil SD, Nichols AC, Yoo J, Fung K, Roth K.

J Robot Surg. 2019 Dec;13(6):773-778. doi: 10.1007/s11701-019-00920-7. Epub 2019 Jan 23.

PMID:
30673979
13.

Variation in the Quality of Head and Neck Cancer Care in the United States.

Strober WA, Sridharan S, Duvvuri U, Cramer JD.

JAMA Otolaryngol Head Neck Surg. 2019 Feb 1;145(2):188-191. doi: 10.1001/jamaoto.2018.3632. No abstract available.

14.

Primary surgery for human papillomavirus-associated oropharyngeal cancer: Survival outcomes with or without adjuvant treatment.

Cramer JD, Ferris RL, Kim S, Duvvuri U.

Oral Oncol. 2018 Dec;87:170-176. doi: 10.1016/j.oraloncology.2018.10.039. Epub 2018 Nov 13.

15.

Transoral Robotic Surgery and the Unknown Primary.

Ofo E, Spiers H, Kim D, Duvvuri U.

ORL J Otorhinolaryngol Relat Spec. 2018;80(3-4):148-155. doi: 10.1159/000490596. Epub 2018 Nov 12. Review.

16.

Transoral surgery using the Flex Robotic System: Initial experience in the United States.

Persky MJ, Issa M, Bonfili JR, Goyal N, Goldenberg D, Duvvuri U.

Head Neck. 2018 Nov;40(11):2482-2486. doi: 10.1002/hed.25375. Epub 2018 Oct 10.

PMID:
30303588
17.

Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives.

Bauman JE, Duvvuri U, Thomas S, Gooding WE, Clump DA, Karlovits B, Wehbe A, Miller FR, Kim S, Sen M, Heron DE, Grandis JR, Argiris A.

Cancer. 2018 Oct 1;124(19):3881-3889. doi: 10.1002/cncr.31651. Epub 2018 Oct 6.

18.

Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Stage I to II Oral Cavity Cancer.

Cramer JD, Sridharan S, Ferris RL, Duvvuri U, Samant S.

Laryngoscope. 2019 Jan;129(1):162-169. doi: 10.1002/lary.27323. Epub 2018 Oct 3.

PMID:
30284248
19.

Staging HPV-related oropharyngeal cancer: Validation of AJCC-8 in a surgical cohort.

Geltzeiler M, Bertolet M, Albergotti W, Gleysteen J, Olson B, Persky M, Gross N, Li R, Andersen P, Kim S, Ferris RL, Duvvuri U, Clayburgh D.

Oral Oncol. 2018 Sep;84:82-87. doi: 10.1016/j.oraloncology.2018.07.013. Epub 2018 Jul 22.

PMID:
30115481
20.

The mutational landscape of recurrent versus nonrecurrent human papillomavirus-related oropharyngeal cancer.

Harbison RA, Kubik M, Konnick EQ, Zhang Q, Lee SG, Park H, Zhang J, Carlson CS, Chen C, Schwartz SM, Rodriguez CP, Duvvuri U, Méndez E.

JCI Insight. 2018 Jul 26;3(14). pii: 99327. doi: 10.1172/jci.insight.99327. eCollection 2018 Jul 26.

21.

Oligometastatic status as predictor of survival in metastatic human papillomavirus-positive oropharyngeal carcinoma.

Albergotti WG, Abberbock S, Mathews F, Ferris RL, Johnson JT, Duvvuri U, Kim S.

Head Neck. 2018 Aug;40(8):1685-1690. doi: 10.1002/hed.25171. Epub 2018 May 13.

PMID:
29756301
22.

Comparison of the seventh and eighth edition american joint committee on cancer oral cavity staging systems.

Cramer JD, Reddy A, Ferris RL, Duvvuri U, Samant S.

Laryngoscope. 2018 Oct;128(10):2351-2360. doi: 10.1002/lary.27205. Epub 2018 Apr 15.

PMID:
29658104
23.

Standardized Margin Assessment Is Needed Before Implementing Negative Margin as a Quality Measure.

Duvvuri U, Johnson JT, Chiosea SI.

JAMA Otolaryngol Head Neck Surg. 2018 Jun 1;144(6):541-542. doi: 10.1001/jamaoto.2018.0074. No abstract available.

PMID:
29596555
24.

Cross-talk Signaling between HER3 and HPV16 E6 and E7 Mediates Resistance to PI3K Inhibitors in Head and Neck Cancer.

Brand TM, Hartmann S, Bhola NE, Li H, Zeng Y, O'Keefe RA, Ranall MV, Bandyopadhyay S, Soucheray M, Krogan NJ, Kemp C, Duvvuri U, LaVallee T, Johnson DE, Ozbun MA, Bauman JE, Grandis JR.

Cancer Res. 2018 May 1;78(9):2383-2395. doi: 10.1158/0008-5472.CAN-17-1672. Epub 2018 Feb 12.

25.

Perineural Invasion in Parotid Gland Malignancies.

Huyett P, Duvvuri U, Ferris RL, Johnson JT, Schaitkin BM, Kim S.

Otolaryngol Head Neck Surg. 2018 Jun;158(6):1035-1041. doi: 10.1177/0194599817751888. Epub 2018 Jan 16.

PMID:
29337642
26.

EGF receptor signaling, phosphorylation, ubiquitylation and endocytosis in tumors in vivo.

Pinilla-Macua I, Grassart A, Duvvuri U, Watkins SC, Sorkin A.

Elife. 2017 Dec 21;6. pii: e31993. doi: 10.7554/eLife.31993.

27.

Positive Margins by Oropharyngeal Subsite in Transoral Robotic Surgery for T1/T2 Squamous Cell Carcinoma.

Persky MJ, Albergotti WG, Rath TJ, Kubik MW, Abberbock S, Geltzeiler M, Kim S, Duvvuri U, Ferris RL.

Otolaryngol Head Neck Surg. 2018 Apr;158(4):660-666. doi: 10.1177/0194599817742852. Epub 2017 Nov 28.

28.

DNA methylation regulates TMEM16A/ANO1 expression through multiple CpG islands in head and neck squamous cell carcinoma.

Finegersh A, Kulich S, Guo T, Favorov AV, Fertig EJ, Danilova LV, Gaykalova DA, Califano JA, Duvvuri U.

Sci Rep. 2017 Nov 9;7(1):15173. doi: 10.1038/s41598-017-15634-9.

29.

Defining the Prevalence and Prognostic Value of Perineural Invasion and Angiolymphatic Invasion in Human Papillomavirus-Positive Oropharyngeal Carcinoma.

Albergotti WG, Schwarzbach HL, Abberbock S, Ferris RL, Johnson JT, Duvvuri U, Kim S.

JAMA Otolaryngol Head Neck Surg. 2017 Dec 1;143(12):1236-1243. doi: 10.1001/jamaoto.2017.2019. No abstract available.

30.

Recent progress of retroauricular robotic thyroidectomy with the new surgical robotic system.

Byeon HK, Holsinger FC, Duvvuri U, Kim DH, Park JH, Chang E, Kim SH, Koh YW.

Laryngoscope. 2018 Jul;128(7):1730-1737. doi: 10.1002/lary.26938. Epub 2017 Oct 25.

PMID:
29068059
31.

Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals.

Shayan G, Kansy BA, Gibson SP, Srivastava RM, Bryan JK, Bauman JE, Ohr J, Kim S, Duvvuri U, Clump DA, Heron DE, Johnson JT, Hershberg RM, Ferris RL.

Clin Cancer Res. 2018 Jan 1;24(1):62-72. doi: 10.1158/1078-0432.CCR-17-0357. Epub 2017 Oct 23.

32.

TMEM16A/ANO1 Inhibits Apoptosis Via Downregulation of Bim Expression.

Godse NR, Khan N, Yochum ZA, Gomez-Casal R, Kemp C, Shiwarski DJ, Seethala RS, Kulich S, Seshadri M, Burns TF, Duvvuri U.

Clin Cancer Res. 2017 Dec 1;23(23):7324-7332. doi: 10.1158/1078-0432.CCR-17-1561. Epub 2017 Sep 12.

33.

Effect of transcervical arterial ligation on the severity of postoperative hemorrhage after transoral robotic surgery.

Kubik M, Mandal R, Albergotti W, Duvvuri U, Ferris RL, Kim S.

Head Neck. 2017 Aug;39(8):1510-1515. doi: 10.1002/hed.24677. Epub 2017 Jun 1.

34.

A prospective evaluation of short-term dysphagia after transoral robotic surgery for squamous cell carcinoma of the oropharynx.

Albergotti WG, Jordan J, Anthony K, Abberbock S, Wasserman-Wincko T, Kim S, Ferris RL, Duvvuri U.

Cancer. 2017 Aug 15;123(16):3132-3140. doi: 10.1002/cncr.30712. Epub 2017 May 3.

35.

Concurrent Chemoradiotherapy in the Adjuvant Treatment of High-risk Primary Salivary Gland Malignancies.

Gebhardt BJ, Ohr JP, Ferris RL, Duvvuri U, Kim S, Johnson JT, Heron DE, Clump DA 2nd.

Am J Clin Oncol. 2018 Sep;41(9):888-893. doi: 10.1097/COC.0000000000000386.

36.

Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancer.

Bauman JE, Duvvuri U, Gooding WE, Rath TJ, Gross ND, Song J, Jimeno A, Yarbrough WG, Johnson FM, Wang L, Chiosea S, Sen M, Kass J, Johnson JT, Ferris RL, Kim S, Hirsch FR, Ellison K, Flaherty JT, Mills GB, Grandis JR.

JCI Insight. 2017 Mar 23;2(6):e90449. doi: 10.1172/jci.insight.90449.

37.

Transoral robotic surgery for management of cervical unknown primary squamous cell carcinoma: Updates on efficacy, surgical technique and margin status.

Geltzeiler M, Doerfler S, Turner M, Albergotti WG, Kubik M, Kim S, Ferris R, Duvvuri U.

Oral Oncol. 2017 Mar;66:9-13. doi: 10.1016/j.oraloncology.2016.12.033. Epub 2017 Jan 6.

PMID:
28249654
38.

Assessment of Surgical Learning Curves in Transoral Robotic Surgery for Squamous Cell Carcinoma of the Oropharynx.

Albergotti WG, Gooding WE, Kubik MW, Geltzeiler M, Kim S, Duvvuri U, Ferris RL.

JAMA Otolaryngol Head Neck Surg. 2017 Jun 1;143(6):542-548. doi: 10.1001/jamaoto.2016.4132.

39.

TMEM16A/ANO1 suppression improves response to antibody-mediated targeted therapy of EGFR and HER2/ERBB2.

Kulkarni S, Bill A, Godse NR, Khan NI, Kass JI, Steehler K, Kemp C, Davis K, Bertrand CA, Vyas AR, Holt DE, Grandis JR, Gaither LA, Duvvuri U.

Genes Chromosomes Cancer. 2017 Jun;56(6):460-471. doi: 10.1002/gcc.22450. Epub 2017 Apr 3.

40.

Transoral robotic surgery for the pediatric head and neck surgeries.

Erkul E, Duvvuri U, Mehta D, Aydil U.

Eur Arch Otorhinolaryngol. 2017 Mar;274(3):1747-1750. doi: 10.1007/s00405-016-4425-3. Epub 2016 Dec 21. Review.

PMID:
28004263
41.

Human Papillomavirus Regulates HER3 Expression in Head and Neck Cancer: Implications for Targeted HER3 Therapy in HPV+ Patients.

Brand TM, Hartmann S, Bhola NE, Peyser ND, Li H, Zeng Y, Isaacson Wechsler E, Ranall MV, Bandyopadhyay S, Duvvuri U, LaVallee TM, Jordan RCK, Johnson DE, Grandis JR.

Clin Cancer Res. 2017 Jun 15;23(12):3072-3083. doi: 10.1158/1078-0432.CCR-16-2203. Epub 2016 Dec 16.

42.

Phase II trial of post-operative radiotherapy with concurrent cisplatin plus panitumumab in patients with high-risk, resected head and neck cancer.

Ferris RL, Geiger JL, Trivedi S, Schmitt NC, Heron DE, Johnson JT, Kim S, Duvvuri U, Clump DA, Bauman JE, Ohr JP, Gooding WE, Argiris A.

Ann Oncol. 2016 Dec;27(12):2257-2262. doi: 10.1093/annonc/mdw428. Epub 2016 Oct 11.

43.

Oncologic outcomes and patient-reported quality of life in patients with oropharyngeal squamous cell carcinoma treated with definitive transoral robotic surgery versus definitive chemoradiation.

Ling DC, Chapman BV, Kim J, Choby GW, Kabolizadeh P, Clump DA, Ferris RL, Kim S, Beriwal S, Heron DE, Duvvuri U.

Oral Oncol. 2016 Oct;61:41-6. doi: 10.1016/j.oraloncology.2016.08.004. Epub 2016 Aug 25.

PMID:
27688103
44.

Association of pretreatment body mass index and survival in human papillomavirus positive oropharyngeal squamous cell carcinoma.

Albergotti WG, Davis KS, Abberbock S, Bauman JE, Ohr J, Clump DA, Heron DE, Duvvuri U, Kim S, Johnson JT, Ferris RL.

Oral Oncol. 2016 Sep;60:55-60. doi: 10.1016/j.oraloncology.2016.07.003. Epub 2016 Jul 7. Review.

45.

A description of the anatomy of the glossopharyngeal nerve as encountered in transoral surgery.

Wang C, Kundaria S, Fernandez-Miranda J, Duvvuri U.

Laryngoscope. 2016 Sep;126(9):2010-5. doi: 10.1002/lary.25706. Epub 2016 Jun 16.

PMID:
27312369
46.

Risk of Severe Toxicity According to Site of Recurrence in Patients Treated With Stereotactic Body Radiation Therapy for Recurrent Head and Neck Cancer.

Ling DC, Vargo JA, Ferris RL, Ohr J, Clump DA, Yau WW, Duvvuri U, Kim S, Johnson JT, Bauman JE, Branstetter BF, Heron DE.

Int J Radiat Oncol Biol Phys. 2016 Jul 1;95(3):973-980. doi: 10.1016/j.ijrobp.2016.02.049.

PMID:
27302512
47.

Utility of the Highly Articulated Flex Robotic System for Head and Neck Procedures: A Cadaveric Study.

Newsome H, Mandapathil M, Koh YW, Duvvuri U.

Ann Otol Rhinol Laryngol. 2016 Sep;125(9):758-63. doi: 10.1177/0003489416653409. Epub 2016 Jun 10.

PMID:
27287677
48.

Utility of up-front transoral robotic surgery in tailoring adjuvant therapy.

Gildener-Leapman N, Kim J, Abberbock S, Choby GW, Mandal R, Duvvuri U, Ferris RL, Kim S.

Head Neck. 2016 Aug;38(8):1201-7. doi: 10.1002/hed.24390. Epub 2016 May 26.

49.

Phase II randomized trial of radiation therapy, cetuximab, and pemetrexed with or without bevacizumab in patients with locally advanced head and neck cancer.

Argiris A, Bauman JE, Ohr J, Gooding WE, Heron DE, Duvvuri U, Kubicek GJ, Posluszny DM, Vassilakopoulou M, Kim S, Grandis JR, Johnson JT, Gibson MK, Clump DA, Flaherty JT, Chiosea SI, Branstetter B, Ferris RL.

Ann Oncol. 2016 Aug;27(8):1594-600. doi: 10.1093/annonc/mdw204. Epub 2016 May 13.

50.

Oncologic outcomes of surgically treated early-stage oropharyngeal squamous cell carcinoma.

Kass JI, Giraldez L, Gooding W, Choby G, Kim S, Miles B, Teng M, Sikora AG, Johnson JT, Myers EN, Duvvuri U, Genden EM, Ferris RL.

Head Neck. 2016 Oct;38(10):1467-71. doi: 10.1002/hed.24456. Epub 2016 Apr 15.

PMID:
27080244

Supplemental Content

Loading ...
Support Center